Biohaven (BHVN) Other Non-Current Assets (2021 - 2026)
Biohaven's (BHVN) quarterly Other Non-Current Assets came in at $45.7 million in Q1 2026, up 18.39% year-on-year from $38.6 million in Q1 2025, and down 3.49% quarter-over-quarter from $47.4 million in Q4 2025.
Biohaven (BHVN) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Biohaven has disclosed Other Non-Current Assets across 6 years of filings, most recently posting $45.7 million for Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $45.7 million, up 18.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $45.7 million (up 18.39% YoY), and the FY2025 annual result was $47.4 million, up 19.83% from the prior year.
- Other Non-Current Assets came in at $45.7 million for Q1 2026 at Biohaven, down from $47.4 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $48.2 million in Q3 2025 to a low of $17.9 million in Q3 2022.
- The 5-year median for Other Non-Current Assets is $36.8 million (2023), against an average of $36.7 million.
- Across the five-year window, Other Non-Current Assets surged 159.82% in 2022 and slipped 9.94% in 2023, its largest moves.
- Biohaven's Other Non-Current Assets stood at $37.5 million in 2022, then retreated by 9.94% to $33.8 million in 2023, then rose by 16.99% to $39.5 million in 2024, then increased by 19.83% to $47.4 million in 2025, then declined by 3.49% to $45.7 million in 2026.
- The last three Other Non-Current Assets figures came in at $45.7 million (Q1 2026), $47.4 million (Q4 2025), and $48.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Biohaven | 1.62 Bn | 1.27 Bn | - | 45.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 45.71 Mn |
| Dec 31, 2025 | 47.36 Mn |
| Sep 30, 2025 | 48.20 Mn |
| Jun 30, 2025 | 37.21 Mn |
| Mar 31, 2025 | 38.61 Mn |
| Dec 31, 2024 | 39.53 Mn |
| Sep 30, 2024 | 31.96 Mn |
| Jun 30, 2024 | 32.92 Mn |
| Mar 31, 2024 | 33.31 Mn |
| Dec 31, 2023 | 33.79 Mn |
| Sep 30, 2023 | 34.71 Mn |
| Jun 30, 2023 | 35.55 Mn |
| Mar 31, 2023 | 36.76 Mn |
| Dec 31, 2022 | 37.51 Mn |
| Sep 30, 2022 | 17.88 Mn |
| Dec 31, 2021 | 14.44 Mn |